Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot P04181: Variant p.Gly375Ala

Ornithine aminotransferase, mitochondrial
Gene: OAT
Feedback?
Variant information Variant position: help 375 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LP/P [Disclaimer] The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance
Residue change: help From Glycine (G) to Alanine (A) at position 375 (G375A, p.Gly375Ala). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Change from glycine (G) to small size and hydrophobic (A) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help 0 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page
Variant description: help In HOGA; decreased protein abundance. Any additional useful information about the variant.
Other resources: help Links to websites of interest for the variant.


Sequence information Variant position: help 375 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 439 The length of the canonical sequence.
Location on the sequence: help ILRNELMKLPSDVVTAVRGK G LLNAIVIKETKDWDAWKVCL The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences. 
Human                         ILRNELMKL---PSDVVTAVRGKGLLNAIVIKETKDW--DAWKVCL

Mouse                         ILRKELMKL---PSDVVTSVRGKGLLNAIVIRETKDC--DA

Rat                           ILRKELMKL---PSDVVTAVRGKGLLNAIVIRETKDC--DA

Bovine                        ILRNELMKL---PSDVVTTVRGKGLLNAIVIRETKDC--DA

Caenorhabditis elegans        LLMSKLKTL---PKDIVSTVRGKGLFCAIVINKKY----DA

Drosophila                    LLRNELSTL---PKDVVSVVRGKGLLNAIVINQKF----DA

Slime mold                    HFRAQISNI---NHPAIQLVRGKGLLNAIVIDPNFTV--SA

Baker's yeast                 SFIAQLKALQAKSNGIISEVRGMGLLTAIVIDPSKANGKTA

Fission yeast                 KFRTALIEC---KSPIVQKVRGRGLLNAVVIDESKTNGRTA
Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 26 – 439 Ornithine aminotransferase, hepatic form
Chain 36 – 439 Ornithine aminotransferase, renal form
Modified residue 362 – 362 N6-acetyllysine; alternate
Modified residue 362 – 362 N6-succinyllysine; alternate
Modified residue 386 – 386 N6-acetyllysine
Modified residue 392 – 392 N6-acetyllysine



Literature citations
Ornithine delta-aminotransferase mutations in gyrate atrophy. Allelic heterogeneity and functional consequences.
Brody L.C.; Mitchell G.A.; Obie C.; Michaud J.; Steel G.; Fontaine G.; Robert M.-F.; Sipila I.; Kaiser-Kupfer M.; Valle D.;
J. Biol. Chem. 267:3302-3307(1992)
Cited for: VARIANTS HOGA HIS-55; LYS-89; PHE-93; LEU-154; THR-180; ALA-184 DEL; LEU-241; CYS-245; PRO-250; ILE-267; LYS-271; ASP-353; ALA-375; ARG-394; PRO-402 AND LEU-417; VARIANT PHE-437; CHARACTERIZATION OF VARIANTS HOGA HIS-55; LYS-89; PHE-93; LEU-154; THR-180; ALA-184 DEL; LEU-241; CYS-245; PRO-250; ILE-267; LYS-271; ASP-353; ALA-375; ARG-394; PRO-402 AND LEU-417; CHARACTERIZATION OF VARIANT PRO-270; FUNCTION; CATALYTIC ACTIVITY; PATHWAY;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.